Please login to the form below
Patent loss
This page shows the latest Patent loss news and features for those working in and with pharma, biotech and healthcare.
Eli Lilly shares adjusted financial guidance for 2023
its loss of patent exclusivity and no expected COVID-19 antibody revenue.
Latest news
-
UK Supreme Court rules in favour of Servier in NHS patent lawsuit
The UK Supreme Court has unanimously ruled in favour of French pharma company Servier over a decade-long patent case filed by the NHS regarding the hypertension drug Coversyl. ... prices. Although the patent on Coversyl expired in 2001, the first generic
-
Janssen’s Erleada improves survival in certain advanced prostate cancer patients
Androgen inhibitor Erleada (apalutamide) is Janssen’s follow-up to its older, blockbuster prostate cancer drug Zytiga (abiraterone acetate), which has now been hit by the loss of patent protection and
-
Amarin shares tumble following Vascepa patent loss
The patent ruling only applies to Vascepa’s US patent exclusivity, with Amarin clarifying that its patents elsewhere in the world still stand.
-
GSK seeks EU approval for Trelegy in adult asthma patients
GSK’s respiratory business has been hit with the loss of patent protection for its COPD blockbuster Seretide/Advair (fluticasone propionate/salmeterol) – Trelegy is GSK’s answer to the increased competition
-
Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls
Revlimid brought in almost $1.3bn between 20 November – when the takeover completed – and the end of the year, but it is facing the loss of patent protection in the US
More from news
Approximately 1 fully matching, plus 155 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
Pfizer is coming off ten years of patent expiries, plus a pipeline that hasn’t yielded as many new products as hoped in that period, and that prompted Bourla to implement ... He has already taken some pretty seismic decisions, such as axing R&D in
-
20 for 2020 – Five pharma companies to watch
There’s also some urgency for the transaction to go quickly and smoothly as AbbVie prepares for the loss of patent protection for $20bn immunology drug Humira (adalimumab) in the US ... AZ’s new growth phase comes after a six-year sales slump thanks
-
Deal Watch October 2018
The termination comes as a consequence of patent infringement litigation which has placed a stay on the FDA’s approval of the biosimilar, Lusduna Nexvue, in the US. ... non‐biologic product post‐patent loss, highlighting the benefits of biologics
-
China: AstraZeneca’s new engine for growth and innovation
years for AZ to return to top-line growth after the patent loss of blockbuster brands such as Nexium and Crestor.
-
Pharma deals during February 2014
given the loss of patent protection on Forest's best selling depression drug Lexapro and another patent cliff looming for Nameda, its Alzheimer's drug in 2015.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest from PMHub
-
Three strategies for managing loss of exclusivity successfully
2. “Price decay after loss of brand exclusivity”. 3. These are just three headlines that come up when you Google “drug patent expiry”. ... 4. It’s no wonder “loss of exclusivity (LOE)” or “the patent cliff” is an ominous prospect for
-
Fishawack Health, a new breed of global commercialization partner, fit for a post pandemic world
We’re designed to solve these challenges by providing integrated, agile solutions across the entire product life cycle, from clinical development to loss of patent.”.
-
Three strategies for managing loss of exclusivity successfully
Price decay after loss of brand exclusivity”. These are just three headlines that come up when you Google “drug patent expiry”. ... It’s no wonder “loss of exclusivity (LOE)” or “the patent cliff” is an ominous prospect for drug
-
How can pharma deliver real value to doctors and earn their trust?
sales in commercial brands in the mature stages, before patent expiry and loss of sales force. ... sales in the mature stages before patent expiry, as well as integrate with the sales force for newer brands.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- BMS presents positive four-year results for Opdivo combination in lung cancer
- AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer
- Medscape Education is Focusing on Patient Centricity and Education Outcomes at EHA 2023
- Pfizer reports positive results for elranatamab in multiple myeloma
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
- Adaptive innovation
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- Navigating patients step by step on their clinical trial journey
No results were found
PMHub
Springer Nature
Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...
Latest intelligence
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
